Alprostadil is a Small Molecule owned by Endo Pharmaceuticals, and is involved in 2 clinical trials, which were completed.

Alprostadil is a prostaglandin analog and prostaglandin E1 agonist. It is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This is because, as a form of prostaglandinE1 (PGE1) it has multiple effects on blood flow. This results in increased pulmonary or systemic blood flow in infants. Alprostadil is administered as intracavernosal injection or as an intraurethral suppository in the treatment of erectile dysfunction. It produce corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.

The revenue for Alprostadil is expected to reach a total of $354m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Alprostadil NPV Report.

Alprostadil is currently owned by Endo Pharmaceuticals. Endo International is the other company associated in development or marketing of Alprostadil.

Alprostadil Overview

Alprostadil (Edex, Viridal, Prostavasin, Viridal Duo) is a naturally occurring form of prostaglandin E1. It is formulated as injectable powder for solution for intracavernous, intravenous and intraareterial route of administration. It is approved for the treatment of erectile dysfunction which is neurogenic, vasculogenic, psychogenic or mixed origin. It is also indicated as an adjunct to the diagnostic evaluation of erectile dysfunction in adult males. Prostavasin also indicated for the treatment of chronic arterial occlusive disease stage III. It was under development for the treatment of dry (atrophic) macular degeneration and critical limb ischemia.

Endo International Overview

Endo International (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceuticals, generic pharmaceuticals, sterile injectables and other products through its operating companies. It sells generic products in the US in various categories including urology, pain management, central nervous system (CNS) disorders, immunosuppression, cancer, cardiovascular diseases and women’s health. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrine disorders and pain management. Endo also provides over-the-counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

The company reported revenues of (US Dollars) US$2,993.2 million for the fiscal year ended December 2021 (FY2021), an increase of 3.1% over FY2020. In FY2021, the company’s operating margin was 0.1%, compared to an operating margin of 17.3% in FY2020. The net loss of the company was US$613.3 million in FY2021, compared to a net profit of US$183.9 million in FY2020. The company reported revenues of US$541.7 million for the third quarter ended September 2022, a decrease of 4.8% over the previous quarter.

Quick View – Alprostadil

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Alprostadil
Administration Pathway
  • Intraarterial
  • Intracavernous
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Male Health
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.